
Julie H Oestreich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5288079/publications.pdf Version: 2024-02-01



LULIE H OESTDEICH

#	Article	IF	CITATIONS
1	2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Annals of Thoracic Surgery, 2012, 94, 1761-1781.	1.3	256
2	Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. Pharmacotherapy, 2014, 34, 1077-1090.	2.6	161
3	Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thrombosis Research, 2008, 121, 527-534.	1.7	156
4	Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist. Journal of Clinical Pharmacology, 2010, 50, 27-35.	2.0	128
5	Traumatic Brain Injury: Central and Peripheral Role of ?7 Nicotinic Acetylcholine Receptors. Current Drug Targets, 2012, 13, 631-636.	2.1	26
6	Game-Based Learning in Pharmacy Education. Pharmacy (Basel, Switzerland), 2022, 10, 11.	1.6	21
7	Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Current Opinion in Investigational Drugs, 2010, 11, 340-8.	2.3	19
8	Clinical Application and Educational Training for Pharmacogenomics. Pharmacy (Basel, Switzerland), 2020, 8, 163.	1.6	17
9	Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. American Heart Journal, 2014, 167, 413-418.	2.7	13
10	Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coronary Artery Disease, 2009, 20, 207-213.	0.7	12
11	Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. Journal of Thrombosis and Thrombolysis, 2014, 38, 372-379.	2.1	9
12	Platelet function analysis: At the edge of meaning. Thrombosis and Haemostasis, 2009, 101, 217-219.	3.4	9
13	Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmacogenomics and Personalized Medicine, 2010, 3, 87.	0.7	6
14	Pharmacodynamic interplay of the P2Y1, P2Y12, and TxA2 pathways in platelets: The potential of triple antiplatelet therapy with P2Y1 receptor antagonism. Thrombosis Research, 2013, 131, e64-e70.	1.7	6
15	Grant deadline: An escape room to simulate grant submissions. Currents in Pharmacy Teaching and Learning, 2021, 13, 848-854.	1.0	6
16	High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the doublestandard dose in an assay-dependent manner. Thrombosis and Haemostasis, 2011, 105, 927-930.	3.4	5
17	Cangrelor in percutaneous coronary intervention. Expert Review of Clinical Pharmacology, 2009, 2, 137-145.	3.1	3
18	Novel Direct-Acting Anticoagulants for Risk Reduction in ACS. Journal of Pharmacy Practice, 2013, 26, 358-366	1.0	3

JULIE H OESTREICH

#	Article	IF	CITATIONS
19	Cangrelor for treatment during percutaneous coronary intervention. Future Cardiology, 2014, 10, 201-213.	1.2	3
20	Digital Storytelling Review in a Pharmacy Self-Care Course. Pharmacy (Basel, Switzerland), 2022, 10, 45.	1.6	2
21	Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects. Thrombosis Journal, 2015, 13, 3.	2.1	1
22	Progress of Antiplatelet Pharmacogenomics. Current Drug Targets, 2011, 12, 1848-1858.	2.1	1